Top Abstract Purchase Related
Home
>
Node
>
Subnode

Factor VIIi concentrate from cold sterilized human plasma

Stephan, W.; Prince, A.M.; Kotitschke, R.

Developments in Biological Standardization 54: 491-495

1983

ISSN/ISBN: 0301-5149
PMID: 6418593
Document Number: 211921
Beta-Propiolactone (beta-PL) in combination with UV irradiation (UV) is an established method for the sterilization of factor IX concentrate or stabilized human serum. Because of the extreme sensitivity of factor VIII to beta-PL, the standard beta-PL/UV procedure cannot be used to obtain hepatitis-safe factor VIII concentrate. It has been shown in chimpanzees that from a cryoprecipitate containing hepatitis non-A, non-B viruses in addition to hepatitis B viruses a factor VIII concentrate (160 U/10 ml) can be prepared by a modified beta-PL/UV procedure, which induces neither hepatitis B nor hepatitis non-A, non-B in experimental animals; the non-sterilized original cryoprecipitate proved to be infectious.

Document emailed within 1 workday
Secure & encrypted payments

Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Uteg, K.H.; Tausenfreund, K.; Schössler, W. 1985: In vitro characterization of human plasma fraction factor VIIi concentrate Die Pharmazie 40(4): 270
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
Simonetti, C.; Casillas, G.; Farías, C.; De los Santos, J.C. 1981: A new human factor VIIi concentrate. Preparation and clinical use Medicina 41 Suppl: 249-252
Cooper, H.A.; Wagner, R.H.; Mosesson, M.W. 1974: The cold-insoluble globulin of plasma and its relationship to factor VIIi Journal of Laboratory and Clinical Medicine 84(2): 258-263
Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Stephan, W. 1982: Fractionation of cold-sterilized plasma. a new concept in production of non-infectious plasma proteins Arzneimittel-Forschung 32(8): 799-801
Andes, W.A. 1983: Factor VIIi concentrate--hepatitis JAMA 249(17): 2331
Allain, J.P.; Steinbuch, M.; Meunier, L.; Muller, J.Y.; Soulier, J.P. 1976: Substitutive treatment of hemopjolia a using a new factor VIIi concentrate La Nouvelle Presse Medicale 5(16): 1047-1050
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Lane, J.L.; Ekert, H.; Vafiadis, A. 1979: Affinity chromatography of human factor VIII using human and rabbit antibodies to Factor VIII Thrombosis and Haemostasis 42(4): 1306-1315
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Kolho, E.; Ebeling, F.; Rasi, V. 1992: Risk of HCV infection in haemophiliacs treated with a dry-heated factor VIII concentrate Thrombosis and Haemostasis 67(6): 728
Kunst, V.A.; Nováková, I.R.; Haanen, C. 1989: Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A Nederlands Tijdschrift Voor Geneeskunde 133(23): 1163-1166
Laurian, Y.; Dussaix, E.; Parquet, A.; Chalvon-Demersay, A.; d'Oiron, R.; Tchernia, G. 1994: Transmission of human parvovirus B19 by plasma derived factor VIIi concentrates Nouvelle Revue Francaise d'Hematologie 36(6): 449-453
Van Vliet, H.H.D.M.; Kappers-Klunne, M.C.; Leebeek, F.W.G.; Michiels, J.J. 2008: PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2 Thrombosis and Haemostasis 100(3): 462-468
Ewing, N.P. 1990: Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors Progress in Clinical and Biological Research 324: 59-68